Aquestive Therapeutics (AQST) Current Assets (2017 - 2026)

Aquestive Therapeutics' Current Assets history runs 10 years deep, the most recent figure standing at $130.2 million for Q1 2026.

• On a quarterly basis, Current Assets rose 46.0% year-over-year to $130.2 million in Q1 2026; TTM through Mar 2026 was $130.2 million, a 46.0% increase from a year earlier, with the FY2025 full-year figure at $149.3 million, up 69.2% from the prior year.
• Current Assets slipped to $130.2 million in Q1 2026 per AQST's latest filing, from $149.3 million in the prior quarter.
• Across five years, Current Assets topped out at $151.7 million in Q3 2025 and bottomed at $38.1 million in Q3 2022.
• The 5-year median for Current Assets is $81.7 million (2025), against an average of $78.5 million.
• Across the five-year window, Current Assets dropped 24.14% in 2022 and soared 161.41% in 2024, its largest moves.
• Year by year, Current Assets stood at $39.9 million in 2022, then increased by 2.7% to $41.0 million in 2023, then jumped by 115.35% to $88.2 million in 2024, then surged by 69.2% to $149.3 million in 2025, then fell by 12.79% to $130.2 million in 2026.
• Per Business Quant, the three latest AQST Current Assets figures stand at $130.2 million (Q1 2026), $149.3 million (Q4 2025), and $151.7 million (Q3 2025).